Hepion Pharmaceuticals Inc Cash Flow Conversion Efficiency
Hepion Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Hepion Pharmaceuticals Inc (HEPA) has a cash flow conversion efficiency ratio of -0.125x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-332.77K) by net assets ($2.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Hepion Pharmaceuticals Inc (2012–2025)
Cash flow conversion efficiency of Hepion Pharmaceuticals Inc from 2012 to 2025. This chart illustrates how Hepion Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Hepion Pharmaceuticals Inc stock quote for real-time trading data and today's change.
Hepion Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Hepion Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Hepion Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hepion Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see market cap of Hepion Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Serabi Gold PLC
LSE:SRB
|
0.137x |
|
Rainbow Rare Earths Limited
LSE:RBW
|
-0.245x |
|
BLOCKMATE VENTURES INC.
F:8MH
|
0.073x |
|
TECIL Chemicals and Hydro Power Limited
NSE:TECILCHEM
|
N/A |
|
Smtrack Bhd
KLSE:0169
|
0.003x |
|
Current Water Technologies Inc
V:WATR
|
-0.016x |
|
Golden Sun Education Group Ltd
NASDAQ:GSUN
|
-0.012x |
|
Shrenik Limited
NSE:SHRENIK
|
0.003x |
Annual Cash Flow Conversion Efficiency for Hepion Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Hepion Pharmaceuticals Inc from 2012 to 2025. Review Hepion Pharmaceuticals Inc (HEPA) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.67 Million | $-3.27 Million | -1.226x | -112.54% |
| 2024-12-31 | $-1.86 Million | $-18.22 Million | 9.776x | +274.08% |
| 2023-12-31 | $7.28 Million | $-40.89 Million | -5.616x | -700.86% |
| 2022-12-31 | $49.86 Million | $-34.96 Million | -0.701x | -108.85% |
| 2021-12-31 | $93.00 Million | $-31.22 Million | -0.336x | +15.84% |
| 2020-12-31 | $40.52 Million | $-16.17 Million | -0.399x | +17.65% |
| 2019-12-31 | $15.62 Million | $-7.57 Million | -0.484x | +93.88% |
| 2018-12-31 | $1.98 Million | $-15.65 Million | -7.922x | -257.35% |
| 2017-12-31 | $3.70 Million | $-8.21 Million | -2.217x | +82.36% |
| 2016-12-31 | $1.32 Million | $-16.56 Million | -12.565x | -346.74% |
| 2015-12-31 | $3.44 Million | $-9.67 Million | -2.813x | -705.22% |
| 2014-12-31 | $-2.93 Million | $-1.36 Million | 0.465x | 0.00% |
| 2013-12-31 | $-2.93 Million | $-1.36 Million | 0.465x | +81819.04% |
| 2012-12-31 | $-140.50K | $-79.70 | 0.001x | -- |
About Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as … Read more